the staff of the Ridgewood blog
Nutley NJ, and CAMBRIDGE, Mass., Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category.
LEQEMBI is the first and only approved treatment for patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease (AD). AD is a type of dementia that affects memory and thinking skills as well as behavior impacting a person’s ability to perform daily activities. It is a chronic neurodegenerative disorder that is both progressive and irreversible, affecting millions in the U.S. 1,2
TIME’s annual list of the Best Inventions features “200 extraordinary innovations changing lives.” To compile the list, TIME solicited nominations from its editors and correspondents around the world, and through an open online application process, paying special attention to growing fields such as AI, green energy, and sustainability. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Take a Wall Street Tour https://www.facebook.com/
